We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Synthetic Bone Graft Recruits Stem Cells for Faster Bone Healing

By HospiMedica International staff writers
Posted on 31 Aug 2010
A new study shows that ceramic biomaterials have the ability to stimulate bone regrowth by attracting proprietary stem cells and growth factors (GFs) to promote bone healing and the integration of the grafted tissue.

Researchers at the Queen Mary, University of London (United Kingdom) and the University of Twente (Enschede, The Netherlands), tested natural bone grafts against various ceramic particles with distinct structural and chemical properties. More...
They found that microporous ceramic particles composed of calcium phosphate--the primary component of bone ash--induced stem cells to develop into bone cells in the test tube and stimulated bone growth in live tissue in mice, dogs, and sheep. According to the researchers, the study shows that the microporosity of the ceramic biomaterials correlates to their propensity to stimulate osteogenic differentiation of stem cells in vitro, as well as bone induction in vivo.

When researchers packed the ceramic particles into a large bone defect in sheep, the bone healed similarly to implants constructed from the animals' own bone, thus demonstrating that osteoinductive ceramics are equally efficient in bone repair as autologous bone grafts. A further benefit is that unlike commercial products that contain artificial GFs, the ceramic biomaterials do not have unwanted side effects such as causing bone fragments to form in nearby soft tissue, such as muscle. The study was published in the August 3, 2010, issue of the Proceedings of the National Academy of Sciences (PNAS).

"The rate of bone repair we see with these materials rivals that of traditional grafts using a patients' own bone,” said lead author Professor Joost de Bruijn, Ph.D., from the school of engineering and materials science at the Queen Mary, University of London. "And what sets it apart from other synthetic graft substitutes is its ability to attract stem cells and the body's natural growth factors, which coincide to form new, strong, natural bone around an artificial graft.”

Although the researchers have not yet identified the mechanism by which these osteoinductive ceramics drive bone growth in the synthetic implants, they note that variations in the ceramic material's chemistry, microporosity, microstructure, and degradation influence the graft's performance.

Related Links:
Queen Mary University of London
University of Twente


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.